Inclusion Criteria:

          1. Histological or biopsy proven adenocarcinoma of the pancreas. Cytology is acceptable
             if histology cannot be obtained.

          2. Newly diagnosed non-metastatic PC judged by tumor board to be feasible for
             (m)FOLFIRINOX and SBRT

          3. Remains non-metastatic (i.e., M0 disease) after 3 months of chemotherapy

          4. Female or male subjects ≥ 18 years of age

          5. ECOG performance status of 0-2

          6. Adequate end-organ function

        Exclusion Criteria:

          1. Subjects with documented metastatic disease

          2. First-line chemotherapy other than (m)FOLFIRINOX and/or chemotherapy given for a total
             period of longer than 4 months prior to start of SBRT

          3. Prior abdominal RT with substantial overlap in radiation fields

          4. Subjects not recovered/controlled from treatment-related toxicities

          5. Uncontrolled malignancy other than PC

          6. Uncontrolled gastric or duodenal ulcer disease within 30 days of dosing

          7. Visible invasion of bulky tumor into the lumen of the bowel or stomach on endoscopy